These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

157 related articles for article (PubMed ID: 15958830)

  • 21. [Current antimalarial drugs recommended by the World Health Organization for the treatment and prevention of malaria].
    Baranova AM
    Med Parazitol (Mosk); 2007; (3):56-9. PubMed ID: 17912843
    [No Abstract]   [Full Text] [Related]  

  • 22. Effect of co-trimoxazole prophylaxis, antiretroviral therapy, and insecticide-treated bednets on the frequency of malaria in HIV-1-infected adults in Uganda: a prospective cohort study.
    Mermin J; Ekwaru JP; Liechty CA; Were W; Downing R; Ransom R; Weidle P; Lule J; Coutinho A; Solberg P
    Lancet; 2006 Apr; 367(9518):1256-61. PubMed ID: 16631881
    [TBL] [Abstract][Full Text] [Related]  

  • 23. [Inappropriate combinations of antiretroviral drugs].
    Machala L; Cerný R
    Klin Mikrobiol Infekc Lek; 2004 Oct; 10(5):241-3. PubMed ID: 15558454
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Drug interactions between proton pump inhibitors and antiretroviral drugs.
    McCabe SM; Smith PF; Ma Q; Morse GD
    Expert Opin Drug Metab Toxicol; 2007 Apr; 3(2):197-207. PubMed ID: 17428151
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Effectiveness of antimalarial drugs.
    Baird JK
    N Engl J Med; 2005 Apr; 352(15):1565-77. PubMed ID: 15829537
    [No Abstract]   [Full Text] [Related]  

  • 26. The epidemiological impact of HIV antiretroviral therapy on malaria in children.
    Greenhalgh S; Ndeffo M; Galvani AP; Parikh S
    AIDS; 2015 Feb; 29(4):473-82. PubMed ID: 25486414
    [TBL] [Abstract][Full Text] [Related]  

  • 27. High risk of neutropenia in HIV-infected children following treatment with artesunate plus amodiaquine for uncomplicated malaria in Uganda.
    Gasasira AF; Kamya MR; Achan J; Mebrahtu T; Kalyango JN; Ruel T; Charlebois E; Staedke SG; Kekitiinwa A; Rosenthal PJ; Havlir D; Dorsey G
    Clin Infect Dis; 2008 Apr; 46(7):985-91. PubMed ID: 18444813
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Adverse interactions with antiretroviral agents: focus on recreational and addiction drugs.
    Vassilev ZP; Marcus SM
    AIDS Read; 2004 Feb; 14(2):96. PubMed ID: 15083804
    [No Abstract]   [Full Text] [Related]  

  • 29. Drug-drug interactions and tolerance in combining antituberculosis and antiretroviral therapy.
    Di Perri G; Aguilar Marucco D; Mondo A; Gonzalez de Requena D; Audagnotto S; Gobbi F; Bonora S
    Expert Opin Drug Saf; 2005 Sep; 4(5):821-36. PubMed ID: 16111446
    [TBL] [Abstract][Full Text] [Related]  

  • 30. New antiretroviral drugs and approaches to HIV treatment.
    Paredes R; Clotet B
    AIDS; 2003; 17 Suppl 4():S85-96. PubMed ID: 15080184
    [No Abstract]   [Full Text] [Related]  

  • 31. Intensive care of patients with HIV infection.
    Huang L; Quartin A; Jones D; Havlir DV
    N Engl J Med; 2006 Jul; 355(2):173-81. PubMed ID: 16837681
    [No Abstract]   [Full Text] [Related]  

  • 32. [The antimalarial effects of piperaquine phosphate and sulphadoxine composite as tested in Hainan Island (author's transl)].
    Qu FY
    Zhonghua Yi Xue Za Zhi; 1981 Jul; 61(7):388-91. PubMed ID: 6805894
    [No Abstract]   [Full Text] [Related]  

  • 33. Importance of spontaneous reporting of adverse reactions associated with antiretroviral drugs in patients with the Human Inmunodeficiency Virus.
    Gallego-Muñoz C; Guerrero-Navarro N; Lorenzo-Martín S
    Enferm Clin; 2017; 27(2):138-139. PubMed ID: 27817983
    [No Abstract]   [Full Text] [Related]  

  • 34. A truvada hypersensitivity reaction simulating abacavir hypersensitivity.
    de Perio MA; Gomez FJ; Frame PT; Fichtenbaum CJ
    AIDS; 2007 Oct; 21(16):2252-3. PubMed ID: 18090057
    [No Abstract]   [Full Text] [Related]  

  • 35. Effects of concurrent exposure to antiretrovirals and cotrimoxazole prophylaxis among HIV-exposed, uninfected infants.
    Ewing AC; King CC; Wiener JB; Chasela CS; Hudgens MG; Kamwendo D; Tegha G; Hosseinipour MC; Jamieson DJ; Van der Horst C; Kourtis AP
    AIDS; 2017 Nov; 31(18):2455-2463. PubMed ID: 28926409
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Free InterApp ARV: The subsequent version of SIMARV® to analyse the clinical relevance of drug interactions with antiretroviral agents in patients with HIV/AIDS.
    Amariles P; Giraldo N; Madrigal-Cadavid J; Granados J
    Res Social Adm Pharm; 2019 Nov; 15(11):1376. PubMed ID: 31353121
    [No Abstract]   [Full Text] [Related]  

  • 37. Contemporary Drug-Drug Interactions in HIV Treatment.
    Devanathan AS; Anderson DJC; Cottrell ML; Burgunder EM; Saunders AC; Kashuba ADM
    Clin Pharmacol Ther; 2019 Jun; 105(6):1362-1377. PubMed ID: 30739315
    [TBL] [Abstract][Full Text] [Related]  

  • 38. HIV and malaria interactions: where do we stand?
    González R; Ataíde R; Naniche D; Menéndez C; Mayor A
    Expert Rev Anti Infect Ther; 2012 Feb; 10(2):153-65. PubMed ID: 22339190
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Antimalarial drugs - what is in use and what is in the pipeline.
    Schlitzer M
    Arch Pharm (Weinheim); 2008 Mar; 341(3):149-63. PubMed ID: 18297679
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Can plant biotechnology help break the HIV-malaria link?
    Vamvaka E; Twyman RM; Christou P; Capell T
    Biotechnol Adv; 2014; 32(3):575-82. PubMed ID: 24607600
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.